Form 4 Filing for Aquestive Therapeutics, Inc. - Officer Stock Grant

This filing details a grant of 67,500 Performance Stock Units (PSUs) to Sherry Korczynski, Chief Commercial Officer of Aquestive Therapeutics, Inc., on March 7, 2025. Each PSU represents a contingent right to one share of common stock, vesting fully on March 7, 2028, provided performance conditions are met. The performance period spans from March 7, 2025, to March 7, 2028. The PSUs were granted with a transaction price of $0.0. The filing was submitted on April 13, 2026, and was noted as being filed late due to an inadvertent administrative oversight. The PSUs are tied to specific pricing periods and Nasdaq closing prices to determine if earned.